Physostigmine effects on phenothiazine-induced extrapyramidal reactions.
D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity; D005116:Extrapyramidal Tracts / Q000187:drug effects*; D005260:Female; D006236:Handwriting; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000235:genetics; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D010830:Physostigmine / Q000627:therapeutic use*; D012459:Salicylates / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000188:drug therapy; D013997:Time Factors; D014268:Trifluoperazine / Q000009:adverse effects* / Q000627:therapeutic use; D014326:Tropanes / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D012459:Salicylates; D014326:Tropanes; D014268:Trifluoperazine; D010830:Physostigmine; D002746:Chlorpromazine